Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17163761 | 0.82 | PDK1 (0.30) | — | |
| SCHEMBL28860958 | 0.80 | KIF11 (0.31) | KIF11 | |
| SCHEMBL5157095 | 0.72 | — | — | |
| SCHEMBL7696252 | 0.62 | TLR8 (0.40) | — | |
| SCHEMBL22867366 | 0.62 | CASP3 (0.37) | KIF11 | |
| SCHEMBL5489913 | 0.61 | — | — | |
| SCHEMBL22971511 | 0.60 | PGR (0.37) | — | |
| SCHEMBL7116955 | 0.60 | KIF11 (0.42) | KIF11 | |
| SCHEMBL3300557 | 0.60 | KIF11 (0.38) | KIF11 | |
| SCHEMBL5007854 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| EP-3478684-B1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | FERMION OY (FI) | 2020-04-15 | — | — | EP | disclosed |
| US-10407427-B2 | Processes for the preparation of Vemurafenib | FERMION OY (FI) | 2019-09-10 | — | — | US | disclosed |
| US-20190194197-A1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | FERMION OY (FI) | 2019-06-27 | — | — | US | disclosed |
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-05-23 | — | — | US | disclosed |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-03-05 | — | — | US | disclosed |
| CN-105683179-B | inhibitors of plasma kallikrein | 卡尔维斯塔制药有限公司 | 2018-10-26 | — | — | CN | disclosed |
| CN-105452240-B | Hete rocyclic derivatives | 卡尔维斯塔制药有限公司 | 2018-06-26 | — | — | CN | disclosed |
| US-7300949-B2 | Thiazolopyrazoles and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300949-B2 | Thiazolopyrazoles and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1732934-A1 | NOVEL THIAZOLOPYRAZOLES AND METHODS OF THEIR USE | Lexicon Genetics Incorporated (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1704147-A1 | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | Pfizer Italia S.r.l. (IT) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005095420-A1 | NOVEL THIAZOLOPYRAZOLES AND METHODS OF THEIR USE | LEXICON GENETICS, INC (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050209269-A1 | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-09-22 | — | — | US | disclosed |
| WO-2005063747-A1 | PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | PFIZER ITALIA S.R.L. (IT) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | KIF11 1070/4885 |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | KIF11 1070/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | KIF11 1070/4885 |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | KIF11 1070/4885 |
| US-10407427-B2 | Processes for the preparation of Vemurafenib | BRAF, NRAS, PDCD1 | KIF11 2801/4885 |
| US-20190194197-A1 | NEW PROCESSES FOR THE PREPARATION OF VEMURAFENIB | BRAF, RAF1, NRAS | KIF11 2695/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | KIF11 308/4885 |
| US-20050209269-A1 | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K6, MAP3K3, MAP3K1 | KIF11 2053/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | KIF11 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.